What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

CLICK HERE FOR CME CREDIT

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology Professor of Medicine Division of Cardiovascular Medicine School of Medicine Oregon Health Sciences University (OHSU) Portland, OR